PharmacoEconomics

The Pros and Cons of a Single ‘Euro-Price’ For Drugs
pp. 271-276(6)
Author: Towse A.

The Role of Cost-Consequence Analysis in Healthcare Decision-Making
pp. 277-288(12)
Authors: Mauskopf J.A.; Paul J.E.; Grant D.M.; Stergachis A.

Applications of Modelling Studies
pp. 289-291(3)
Authors: Nuijten M.J.C.; Starzewski J.

The Economics of Parallel Trade
pp. 293-304(12)
Author: Danzon P.M.

The Selection of Data Sources For Use in Modelling Studies
pp. 305-316(12)
Author: Nuijten M.J.C.

A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe
pp. 317-326(10)
Authors: Hood S.C.; Annemans L.; Rutten -van Mölken M.

Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV-Positive Adult Men and Women
pp. 327-336(10)
Authors: Anis A.H.; Hogg R.S.; Yip B.; Wang X-h.; Montaner J.S.G.; O'Shaughnessy M.V.; Schechter M.T.

Cost-Effectiveness Analysis of Early Lisinopril Use in Patients With Acute Myocardial Infarction: Results From GISSI-3 Trial
pp. 337-346(10)
Authors: Franzosi M.G.; Maggioni A.P.; Santoro E.; Tognoni G.; Cavalieri E.

Economic Evaluation of Insulin Lispro versus Neutral (Regular) Insulin Therapy Using a Willingness-To-Pay Approach
pp. 347-358(12)
Authors: Davey P.; Grainger D.; MacMillan J.; Rajan N.; Aristides M.; Dobson M.

Meropenem: A Pharmacoeconomic Review of its Use in Serious Infections
pp. 359-377(19)
Authors: Holliday S.M.; Benfield P.